The DOI matches its Crossref record; 26 of the 26 references it cites were found in a registry or an index.
An overview of GLP-1 agonists and recent cardiovascular outcomes trials
Open accessAbstract
Glucagon-like peptide 1 receptor agonists (GLP-1 RAs) are emerging as an important therapy to consider for patients with type 2 diabetes (T2D) given this class of treatment's ability to reduce glycated haemoglobin and their associated weight loss and low risk for hypoglycaemia. Additionally, seven cardiovascular outcomes trials (CVOTs) have been performed in the past 4 years using lixisenatide, liraglutide, semaglutide, exenatide, albiglutide, dulaglutide and oral semaglutide. All have found non-inferiority for cardiovascular outcomes, with many finding superiority of these drugs. These findings have transformed our guidelines on pharmacological treatment of T2D. This review article will discuss GLP-1 RA therapy, review the seven CVOTs reported to date and discuss the implications on current guidelines and therapies going forward.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Sodium-glucose co-transporter-2 inhibitors (SGLT2i) and glucagon-like peptide-1 receptor agonists (GLP1ra) are novel classes of medications for type 2 diabetes that significantly reduce cardiovascular deaths independent of their effect on hyperglycemia and are widely endorsed by clinical practice guidelines.4–11”
From Disparities in Use of Novel Diabetes Medications by Insurance: A Nationally Representative Cohort Study (2024) · cites this paper as [7]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“Sodium-glucose co-transporter-2 inhibitors (SGLT2i) and glucagon-like peptide-1 receptor agonists (GLP1ra) are novel classes of medications for type 2 diabetes that significantly reduce cardiovascular deaths independent of their effect on hyperglycemia and are widely endorsed by clinical practice guidelines.4–11”
From Disparities in Use of Novel Diabetes Medications by Insurance: A Nationally Representative Cohort Study (2024) · cites this paper as [7]
The cited source says what the claim attributes to it.
In the citing paper
“Trials in people with type 2 diabetes have shown convincing reductions in cardiovascular events with some GLP-1 RA (259); whether these benefits would also be seen in people with type 1 diabetes is unknown.”
In the citing paper
“In recent years, seven trials have demonstrated their superiority or almost non-inferiority for CV outcomes, indicating advantageous cardio-protective effects [170].”
From Dysregulated epicardial adipose tissue as a risk factor and potential therapeutic target of heart failure with preserved ejection fraction in diabetes (2022) · cites this paper as [170]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Effects of Intensive Glucose Lowering in Type 2 Diabetes
(2008) · New England Journal of Medicine · doi:10.1056/nejmoa0802743 · Cited by 7,888
10-year follow-up of intensive glucose control in type 2 diabetes
Holman, R. R., Paul, S. K., Bethel, M. A., Matthews, D. R., & Neil, H. A. W. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa0806470 · Cited by 7,751
Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes
Marso, S. P., Daniels, G. H., Brown-Frandsen, K., Kristensen, P., Mann, J. F. E., Nauck, M. A., Nissen, S. E., Pocock, S., Poulter, N. R., Ravn, L. S., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1603827 · Cited by 7,629 · cited 1×
“InTroduCTIon It was first reported in 1964 that there was greater and more sustained insulin release in response to an oral glucose load when compared with the same glucose load given intravenously.(1) With the discovery of an incretin hormone known as glucosedependent insulinotropic polypeptide (GIP), this enhanced r…”
BackgroundSemaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes
Marso, S. P., Bain, S. C., Consoli, A., Eliaschewitz, F. G., Jódar, E., Leiter, L. A., Lingvay, I., Rosenstock, J., Seufert, J., Warren, M. L., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1607141 · Cited by 6,900 · cited 1×
“With the discovery of an incretin hormone known as glucosedependent insulinotropic polypeptide (GIP), this enhanced release of insulin in response to ingestion of glucose became known as the ‘incretin effect’.(2) In 1986, Nauck et al showed that despite similar levels of GIP in response to an oral glucose load, patien…”
BackgroundCosentino, F., Grant, P. J., Aboyans, V., Bailey, C. J., Ceriello, A., Delgado, V., Federici, M., Filippatos, G., Grobbee, D. E., Hansen, T. B., et al. (2020) · European Heart Journal · doi:10.1093/eurheartj/ehz486 · Cited by 4,763
Effect of Rosiglitazone on the Risk of Myocardial Infarction and Death from Cardiovascular Causes
Nissen, S. E., & Wolski, K. (2007) · New England Journal of Medicine · doi:10.1056/nejmoa072761 · Cited by 4,675
Drucker, D. J., & Nauck, M. A. (2006) · The Lancet · doi:10.1016/s0140-6736(06)69705-5 · Cited by 3,896
Gerstein, H. C., Colhoun, H. M., Dagenais, G. R., Diaz, R., Lakshmanan, M., Pais, P., Probstfield, J., Riesmeyer, J. S., Riddle, M. C., Rydén, L., et al. (2019) · The Lancet · doi:10.1016/s0140-6736(19)31149-3 · Cited by 3,163
Lixisenatide in Patients with Type 2 Diabetes and Acute Coronary Syndrome
Pfeffer, M. A., Claggett, B., Diaz, R., Dickstein, K., Gerstein, H. C., Køber, L. V., Lawson, F. C., Ping, L., Wei, X., Lewis, E. F., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1509225 · Cited by 2,409
Effects of once-weekly exenatide on cardiovascular outcomes in type 2 diabetes
Holman, R. R., Bethel, M. A., Mentz, R. J., Thompson, V. P., Lokhnygina, Y., Buse, J. B., Chan, J. C., Choi, J., Gustavson, S. M., Iqbal, N., et al. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1612917 · Cited by 2,162
Research works printed but not linked: 1
- Food and Drug Administration, 2008, Diabetes mellitus-evaluating cardiovascular risk in new antidiabetic therapies to treat type 2 diabetes
Cited by
Sorted by citations
Items 101–195 of 195
Kroopnick, J. M., & Davis, S. N. (2022) · Expert Opinion on Pharmacotherapy · doi:10.1080/14656566.2022.2089021 · Cited by 6
Meiring, S., Busch, C. B. E., van Baar, A. C. G., Hemke, R., Holleman, F., Nieuwdorp, M., & Bergman, J. J. G. H. M. (2022) · Cardiovascular Diabetology · doi:10.1186/s12933-022-01628-z · Cited by 7
Insights into the structural dynamics of the secretin family (class B1) G protein-coupled receptors
Liu, T., Naidoo, N. R., Agyemang, E., & Lamichhane, R. (2025) · Journal of Biological Chemistry · doi:10.1016/j.jbc.2025.110466 · Cited by 9
Blonde, L., Fainberg, U., Kaltoft, M. S., Mosenzon, O., Ramesh, C. K., & Rea, R. R. (2021) · Diabetes Obesity and Metabolism · doi:10.1111/dom.14464 · Cited by 4
What about glucagon-like peptide-1 receptor agonist for all? Recent data and perspectives
Sabouret, P. F., Ecarnot, F., Rosa, S. D., & Ray, K. K. (2023) · European Heart Journal · doi:10.1093/eurheartj/ehad632 · Cited by 5
Rajagopal, D., Rashid, S. A., Prasad, M., & Fareed, M. (2024) · Cureus · doi:10.7759/cureus.65910 · Cited by 8
A System-Based Review on Effects of Glucagon-Like Peptide-1 Receptor Agonists: Benefits vs Risks
Fadel, L. P., Thao, G., Chitre, T., Rojas, E. D., Fricko, M. N., Domingo, V., Budginas, B., Guerrero, L. C., Ghatas, M., Arani, N. T., et al. (2025) · Cureus · doi:10.7759/cureus.78575 · Cited by 5
Pladevall, M., ZIEMIECKI, R. M., Johannes, C. B., Khan, A. M., Mines, D. I., Ebert, N., Kovesdy, C. P., Thomsen, R. W., Baak, B. N., García‐Sempere, A., et al. (2025) · Diabetes Therapy · doi:10.1007/s13300-025-01717-8 · Cited by 5
Yoon, J. H., Hong, A. R., Choi, W., Park, J. Y., Kim, H. K., & Kang, H. (2021) · Chonnam Medical Journal · doi:10.4068/cmj.2021.57.3.211 · Cited by 5
Rella, S., Onyiah, J. C., Baker, C., Singh, V., Her, A., & Rasouli, N. (2023) · Therapeutic Advances in Endocrinology and Metabolism · doi:10.1177/20420188231207348 · Cited by 6
Reilly-Harrington, N. A., Himes, S. M., Lauretti, J. M., & Sogg, S. (2025) · Cognitive and Behavioral Practice · doi:10.1016/j.cbpra.2025.02.004 · Cited by 4
Sun, M., Wang, X., Lu, Z., Yang, Y., Lv, S., Miao, M., Chen, W., Wu, S., & Zhang, J. (2025) · Diabetes Obesity and Metabolism · doi:10.1111/dom.16434 · Cited by 6
Salmen, T., Rizvi, A. A., Rizzo, M., Pietroșel, V.-A., Bica, I.-C., Diaconu, C.-T., Potcovaru, C.-G., Salmen, B.-M., Coman, O. A., Bobirca, A. V., et al. (2023) · Biomedicines · doi:10.3390/biomedicines11092455 · Cited by 4
Job Satisfaction among Primary Health Care Workers in Buraidah, Qassim, Saudi Arabia
Aljumail, E., & Rabbani, U. (2021) · World Family Medicine Journal/Middle East Journal of Family Medicine · doi:10.5742/mewfm.2021.94173 · Cited by 4
Emerging drug delivery strategies for local immunomodulation in atherosclerosis
Nunes, C., Kramer, A., & Volpatti, L. R. (2025) · Journal of Controlled Release · doi:10.1016/j.jconrel.2025.114261 · Cited by 4
Kumar, S. R., Anderson, J. E., Coviello, A. D., Lopez-Jimenez, F., & Bakris, G. L. (2026) · JACC Advances · doi:10.1016/j.jacadv.2025.102465 · Cited by 4
Diabetic Kidney Disease: From Pathophysiology to Treatment Perspectives
Varda, L., Vreča, N., Ekart, R., Bevc, S., & Piko, N. (2026) · Kidney & Blood Pressure Research · doi:10.1159/000550085 · Cited by 9
Possible dulaglutide-associated cholecystitis with safe continuation post cholecystectomy
Butler, J., Bjurstrom, M., & Marceau, A. (2021) · American Journal of Health-System Pharmacy · doi:10.1093/ajhp/zxab045 · Cited by 3
Gill, G. S., Latif, A., Hilleman, D. E., Lavie, C. J., & Alla, V. M. (2021) · Current Problems in Cardiology · doi:10.1016/j.cpcardiol.2021.100878 · Cited by 3
Glucose lowering does not necessarily reduce cardiovascular risk in type 2 diabetes
Bourazana, A., Giamouzis, G., Skoularigis, J. S., Triposkiadis, F. K., & Xanthopoulos, A. V. (2022) · World Journal of Cardiology · doi:10.4330/wjc.v14.i4.266 · Cited by 4
Alasmari, I. H., Saleh, M. M. A., Alahmari, M. A., Asiri, S. M., & Asiri, A. Y. (2021) · World Family Medicine Journal/Middle East Journal of Family Medicine · doi:10.5742/mewfm.2021.94184 · Cited by 3
Alomary, S. A., Alorainy, B. A., Albargan, N. S., Alotaibi, F. Z., & Alkholaiwi, F. (2021) · World Family Medicine Journal/Middle East Journal of Family Medicine · doi:10.5742/mewfm.2021.94191 · Cited by 3
Şermet, S., Çam, M. E., Hazar‐Yavuz, A. N., Taşkın, T., Kabatas, G. S., Yazır, Y., Kabasakal, L., & Elçioğlu, H. K. (2023) · Obesity Medicine · doi:10.1016/j.obmed.2023.100517 · Cited by 3
Peppa, Μ., Manta, A., Mavroeidi, I., Asimakopoulou, A., Syrigos, A., Nastos, C., Pikoulis, E. A., & Κόλλιας, Α. (2023) · Pharmaceutics · doi:10.3390/pharmaceutics15112526 · Cited by 3
GLP-1 Receptor Agonists: Beyond Diabetes—What the Neurosurgeon Needs to Know
Abdulrazeq, H., Taman, M., Ali, R., Doberstein, C., Sullivan, P. Z., Sampath, P., Telfeian, A. E., Gokaslan, Z. L., Fridley, J., & Asaad, W. F. (2024) · Neurosurgery Open · doi:10.1227/neuprac.0000000000000098 · Cited by 3
Emirates consensus recommendations on cardiovascular risk management in type 2 diabetes
Sabbour, H. M., Almahmeed, W. A., Alawadi, F., Shehab, A. M., Zubaidi, A. A., Bashier, A. M., Ghulam, A. R., Rashid, F., Zaky, H., Kassem, H. H., et al. (2025) · Frontiers in Endocrinology · doi:10.3389/fendo.2024.1395630 · Cited by 3
A revolution in diabetes care: novel drugs and new recommendations
Lüscher, T. F. (2020) · European Heart Journal · doi:10.1093/eurheartj/ehz966 · Cited by 4
Altaf, M., Altaf, L. Z., Farahat, F. M., & Althaqafi, A. (2021) · World Family Medicine Journal/Middle East Journal of Family Medicine · doi:10.5742/mewfm.2021.94170 · Cited by 3
Ölmestig, J. N. E., Marlet, I. R., Vilsbøll, T., Rungby, J., Rostrup, E., Lambertsen, K. L., & Kruuse, C. R. (2022) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2022.899389 · Cited by 3
Should Hemoglobin A1c Targets Be Re-Evaluated?
Kumar, M., & Thompson, P. D. (2022) · The American Journal of Cardiology · doi:10.1016/j.amjcard.2022.02.017 · Cited by 4
Beak, J. Y., Lee, K., Im, B. N., Kwon, T. K., Im, H. T., Cho, J. H., & Cho, H. J. (2025) · Journal of Pharmaceutical Investigation · doi:10.1007/s40005-025-00752-8 · Cited by 2
Kim, J.-W. (2025) · Journal of Yeungnam Medical Science · doi:10.12701/jyms.2025.42.61 · Cited by 2
Observation of unique stable nano-assemblies of a lipidated glucagon-like peptide 1 analogue.
Brichtová, E. P., dos Santos, A. L. G., & Jackson, S. E. (2025) · Soft Matter · doi:10.1039/d5sm00801h · Cited by 2
The Hidden Link Between Endometriosis and Obesity: A State-of-the-Art Review
Desai, S., Reed, C. C., Mendez, Y. H., Yang, Q., & Guan, X. (2026) · Cureus · doi:10.7759/cureus.102896 · Cited by 2
Brunel, F. M., Parlee, S. D., Li, P., Lu, W., Chabenne, J. R., Pérez–Tilve, D., Finan, B., Kharitonenkov, A., & DiMarchi, R. D. (2026) · Biochemistry · doi:10.1021/acs.biochem.5c00820 · Cited by 2
Glycemic Control in Hospitalized Stroke Patients: A Review
Patel, V. N., & Kuo, E. (2021) · Current Diabetes Reports · doi:10.1007/s11892-021-01416-1 · Cited by 2
Novel Treatments and the Future of DKD: What Is on the Horizon?
Wu, H., & Batuman, V. (2022) · Springer eBooks · doi:10.1007/978-3-030-86020-2_28 · Cited by 2
School Teachers’ Knowledge and Attitude toward School Students with Epilepsy
Alsugair, R. S., Alyabis, M. A., Algadi, M. A., Attieh, A. I., Juha, L. A., Alawa, R. G., Alghannam, S. G., Alsaadoon, N. Z., El-Sayed, N., & Alfadeel, M. A. (2021) · World Family Medicine Journal/Middle East Journal of Family Medicine · doi:10.5742/mewfm.2021.94183 · Cited by 2
El-Gamal, F., Alsubhi, N., Badr, S., Althaqafi, N., Al-Qadasi, F., & Hammed, M. (2021) · World Family Medicine Journal/Middle East Journal of Family Medicine · doi:10.5742/mewfm.2021.94179 · Cited by 2
Pandya, N., & Patel, M. (2024) · Springer eBooks · doi:10.1007/978-3-030-74720-6_38 · Cited by 2
Drake, E. S., Marino, A. B., Theroux, J. D., & Roberts, K. (2024) · The Nurse Practitioner · doi:10.1097/01.npr.0000000000000216 · Cited by 2
Ferreira, E. V. M., Oliveira, R. K. F., Salomão, R., Brunialti, M. K. C., Cardoso, M. B. A., Chen, C.-N., Zhao, L., & McCabe, C. (2025) · Infectious Disease Reports · doi:10.3390/idr17010005 · Cited by 2
Khan, L. A., Sadia, K., Naveed, R., Khalid, R., Faisal, R., Bilal, A. R., Nawaz, A., Safdar, A., Siddique, T. S. B., Ahmad, S., et al. (2025) · Journal of Diabetes & Metabolic Disorders · doi:10.1007/s40200-025-01741-2 · Cited by 2
Manyari, D. E., Belenkie, I., & Quiroz, O. G. (2023) · Springer eBooks · doi:10.1007/978-3-031-17650-0_31 · Cited by 2
Tschöpe, C., Elsanhoury, A., Nelki, V., Linthout, S. V., Kelle, S., & Remppis, A. (2021) · Der Internist · doi:10.1007/s00108-021-01182-y · Cited by 3
Ezeani, I. U., Eregie, A., & Ohwovoriole, A. E. (2021) · Annals of Health Research (The Journal of the Medical and Dental Consultants Association of Nigeria OOUTH Sagamu Nigeria) · doi:10.30442/ahr.0703-02-131 · Cited by 1
Baun, M. D., & Page, G. (2025) · Journal of the American Osteopathic Academy of Orthopedics · doi:10.70709/r2fykae2uu · Cited by 1
History repeating itself: anti-fat narratives in the ozempic and Fen-Phen eras
Basinger, E. D., & Watford, M. L. (2026) · Fat Studies · doi:10.1080/21604851.2026.2632416 · Cited by 1
O’Brien, H., & Travis, C. (2022) · Primary Care Clinics in Office Practice · doi:10.1016/j.pop.2021.11.010 · Cited by 1
Obesity, weight loss and gynecologic neoplasms: a narrative review
Halpern, B., & Mendes, T. B. (2022) · Women & Health · doi:10.1080/03630242.2022.2066747 · Cited by 1
Effectiveness of Community Mental Health Service in Oman: A Pilot Study
Al-Jadidi, S., Aboalatta, A. S., Al-Rahbi, I., Al-Harrasi, M., AlRauzaiqi, H., Sabeih, M. A., AlGammari, T., & Al-Shammakhi, A. (2021) · World Family Medicine Journal/Middle East Journal of Family Medicine · doi:10.5742/mewfm.2021.94180 · Cited by 1
Mohanan, P. P., & Jariwala, P. V. (2022) · Indian Heart Journal · doi:10.1016/j.ihj.2022.11.010 · Cited by 2
Peasah, S. K., Huang, Y., Palli, S. R., Swart, E. C. S., Donato, B. M. K., Pimple, P. M., Bovier, J., Manolis, C. H., & Good, C. B. (2023) · Journal of Managed Care & Specialty Pharmacy · doi:10.18553/jmcp.2023.29.2.152 · Cited by 1
Clinical progress note: Glucagon‐like peptide‐1 receptor agonists and hospitalized patients
Ravee, A., Burroughs‐Ray, D., Jackson, C., Spratt, S. E., & Sata, S. S. (2024) · Journal of Hospital Medicine · doi:10.1002/jhm.13357 · Cited by 1
Relevant Pharmacology and Interventions
Watson, A., & Hand, S. (2024) · Springer eBooks · doi:10.1007/978-3-031-72862-4_3 · Cited by 1
Increased Psychological Disorders among Pediatric Population during Covid
AlQaatri, H. A. J. H. (2021) · World Family Medicine Journal/Middle East Journal of Family Medicine · doi:10.5742/mewfm.2021.94174 · Cited by 1
Prevention of Coronary Atherosclerosis
Figtree, G. A., Kott, K. A., & Vernon, S. T. (2023) · Springer eBooks · doi:10.1007/978-3-031-25879-4_3 · Cited by 1
Effect of treatment with GLP-1R agonists on the urinary peptidome of T2DM patientsPreprint
Lohia, S., Siwy, J., Mavrogeorgis, E., Eder, S., Thöni, S., Mayer, G. J., Mischak, H., Vlahou, A., & Jankowski, V. (2023) · medRxiv · doi:10.1101/2023.05.03.23289439 · Cited by 1
Pathogenesis of Macrovascular Complications in Diabetes
Østergaard, J. A., Block, T. J., Dahm, S. I., Khan, W., & Jandeleit-Dahm, K. A. M. (2024) · Wiley eBooks · doi:10.1002/9781119697473.ch46 · Cited by 1
Ramalan, M. A., Maiyaki, M. B., Gezawa, I., & Uloko, A. E. (2024) · medRxiv · doi:10.1101/2024.07.18.24310630 · Cited by 1
Paradigm shift in the management of DM & CVD —preventing the next CV event
Handelsman, Y., & Bloomgarden, Z. T. (2020) · Journal of Diabetes · doi:10.1111/1753-0407.13079
Torkos, S., Burke, J. M., & Zaiken, K. (2020) · Journal of Pharmacy Technology · doi:10.1177/8755122520949449
Mascolo, A., Scavone, C., Scisciola, L., Chiodini, P., Capuano, A., & Paolisso, G. (2021) · Pharmacological Research · doi:10.1016/j.phrs.2021.105863
Changing the way type 2 diabetes is managed
Syed, H., & Jenkinson, D. (2021) · Journal of Prescribing Practice · doi:10.12968/jprp.2021.3.10.412
Pandya, N., & Patel, M. (2021) · Springer eBooks · doi:10.1007/978-3-030-01782-8_38-1
What Do You Need to Know About GLP-1 Receptor Agonists?
Carmichael, K. A. (2022) · Consultant · doi:10.25270/con.2022.02.00004
Managing TIA: Early action and essential risk-reduction steps
Rundell (2022) · The Journal of Family Practice · doi:10.12788/jfp.0398
Ahmed, S. F., Alghamdi, G. A., Albalawi, A. A., AlQahtani, M., Ghonim, I. M., Elhady, H. M., Abdelhamid, S. A., & Eldesouky, A. A. (2021) · World Family Medicine Journal/Middle East Journal of Family Medicine · doi:10.5742/mewfm.2021.94189
Ballaji, W. K., & Hadadi, H. M. (2021) · World Family Medicine Journal/Middle East Journal of Family Medicine · doi:10.5742/mewfm.2021.94186
Barriers to Compliance of Hypertensive Patients in Abha City, Saudi Arabia
Almonawar, A. A., Alasmary, A. S., Mogbel, M. M., & Almojamad, H. M. (2021) · World Family Medicine Journal/Middle East Journal of Family Medicine · doi:10.5742/mewfm.2021.94177
Role of SGLT2 Inhibitors and GLP-1 Analogs in Cardiovascular Risk Reduction in Type 2 Diabetes
Rashed, M. H., Dauyoumor, T. D., Corney, S. M., Konono, K., Joubert, N., Mohamed, M., Sukhoo-Pertab, M., Makhomisane, M., Njeri, I., Mwita, J. C., et al. (2021) · World Family Medicine Journal/Middle East Journal of Family Medicine · doi:10.5742/mewfm.2021.94188
Environmental Triggers in Migraine patients in Riyadh: A Cross-Sectional Study
Harbi, A. A., Alzahrani, N. H., Alsuhibany, H. A., Aldosari, M. A. A., Alsalman, R. S., & Alkhalifah, A. (2021) · World Family Medicine Journal/Middle East Journal of Family Medicine · doi:10.5742/mewfm.2021.94172 · Cited by 1
Diagnostic approach to eosinophilia in children
Shasho, R. (2021) · World Family Medicine Journal/Middle East Journal of Family Medicine · doi:10.5742/mewfm.2021.94190
Knowledge, Attitude and Practice of Non-Psychiatric Physicians about Addiction
Al-Ahmari, S. M., Almusa, A. A., Alshomrani, A. A., Ahmary, W. S. H. A., Assiry, Z. S. A., Alqahtany, S. M. S., Asiri, A. Y., Alqahtani, T. S., Alassiri, N. S., & Mostafa, O. A. (2021) · World Family Medicine Journal/Middle East Journal of Family Medicine · doi:10.5742/mewfm.2021.94185
Clark, K. A. A., & Morris, A. A. (2022) · Journal of Cardiac Failure · doi:10.1016/j.cardfail.2022.12.002
Sewell, J., & Johnson, R. (2022) · Physician Assistant Clinics · doi:10.1016/j.cpha.2022.10.007
The Predictive Value of Glucagon-Like Peptide 1 Plasma Levels on Acute Heart Failure
Wahyudi, M. F., Suparyatmo, J., & Ariningrum, D. (2022) · INDONESIAN JOURNAL OF CLINICAL PATHOLOGY AND MEDICAL LABORATORY · doi:10.24293/ijcpml.v28i2.1838
Drapkina, O. M., Блохина, А. В., Borisova, A. L., Bukaeva, A. A., Voshev, D. V., Garbuzova, E. V., Dzhioeva, O. N., Drozdova, L. Y., Олеговна, Е. С., Ershova, A. I., et al. (2023) · doi:10.15829/ropniz-d95-2023
The entero-insular axis and metabolic syndrome
Sarkar, J., & Chakrabarti, P. (2024) · Elsevier eBooks · doi:10.1016/b978-0-323-85732-1.00047-5
Injectable Therapies for Diabetes and Obesity: From Evolution to Revolution
Abdelghadir, E., Houri, M., & Khalil, A. (2024) · Journal of Diabetes and Endocrine Practice · doi:10.1055/s-0043-1778117
Gurian, A. D. O. V., Teles, A. E. L., Bozi, A., Mantovi, C. K., Moreira, F. G., da Silva, F. M. A., Gonçalves, L. B., Silveira, T. L. D. S., da Silva, T. B., & Lista, P. V. (2024) · EPITAYA eBooks · doi:10.47879/ed.ep.2024479p121
Garzaie, A. A. A., Taib, H., Dalbhi, S. A., Khan, M. S., & Kofi, M. A. (2024) · European Journal of Medical and Health Research · doi:10.59324/ejmhr.2024.2(5).07
Impact of a Restrictive Formulary on glycemic control compared with an Open Formulary
Duong, T., Jolliff, J. C., Duvall, A., Aguirre, R., & Lash, D. B. (2024) · JACCP JOURNAL OF THE AMERICAN COLLEGE OF CLINICAL PHARMACY · doi:10.1002/jac5.2048
Applications and Challenges of Oral Peptide Drug Delivery in Diabetes Treatment
Feng, Y. (2025) · Theoretical and Natural Science · doi:10.54254/2753-8818/2025.20300
The developmental trajectory of GLP-1 receptor agonists
Kou, B., & Qian, H. (2025) · Elsevier eBooks · doi:10.1016/b978-0-443-27402-2.00001-2
Plant Growth Promotion Induced by Phosphate Solubilizing Endophytes from the Tropics
Pedrino, I. C., Fernandes, A. C. V., Fávero, A. P., & Lacava, P. T. (2025) · Springer eBooks · doi:10.1007/978-3-031-90530-8_9
Haider, S., Chand, P., & Kumar, A. (2025) · The Journal of Medical Research · doi:10.4103/jmr.jmr_48_25
OE, Y., Nomoto, H., Cho, K. Y., Yokozeki, K., Ono, T., Miya, A., Kameda, H., Nakamura, A., Arimura, Y., & Atsumi, T. (2024) · Figshare · doi:10.6084/m9.figshare.26367932
OE, Y., Nomoto, H., Cho, K. Y., Yokozeki, K., Ono, T., Miya, A., Kameda, H., Nakamura, A., Arimura, Y., & Atsumi, T. (2024) · Figshare · doi:10.6084/m9.figshare.26368536
Meiring, S., Busch, C. B. E., van Baar, A. C. G., Hemke, R., Holleman, F., Nieuwdorp, M., & Bergman, J. J. G. H. M. (2022) · Figshare · doi:10.6084/m9.figshare.21191998
Cardioprotective therapy in type 2 diabetes guided by a proteomic risk model: A randomized trial
Gill, R. D., Carpenter, M. A., Holstein, A., Garcia, A. R., Alkholder, A., Gupta, A., Singh, V., Quyyumi, A. A., Rasouli, N., Neeland, I. J., et al. (2026) · American Journal of Preventive Cardiology · doi:10.1016/j.ajpc.2026.101426 · Cited by 1
The Role of GLP-1 Agonists in Weight Management: Barriers, Effectiveness, and Safety Perceptions
Silwal, P., Dilley, A., Adhikari, S., Lusk, J. L., & McFadden, B. R. (2026) · Drugs & Therapy Perspectives · doi:10.1007/s40267-026-01243-y
Efficacy of glucagon-like-peptide-1 agonists for weight loss in adults with CHD
Varghese, P., Elder, R. W., Vinocur, J. M., Spatz, E. S., Shabanova, V., McCollum, S., Harper, M., & Pastor, T. A. (2026) · Cardiology in the Young · doi:10.1017/s1047951126113109
Caimi, E., Ghetti, E. M., Giovagnoli, F., Vaccari, S., Ceglia, G., Cavallero, M. F., Comunian, R., Giuli, R. D., Veronesi, A., Klinger, F. M., et al. (2026) · Aesthetic Plastic Surgery · doi:10.1007/s00266-026-06155-w
Cardiovascular Health and Healthy Aging
ANANTHARAMAKRISHNAN, B., Obholz, J., Nwaedozie, S. T., & Kumar, M. (2026) · Springer eBooks · doi:10.1007/978-3-032-21928-2_5
Metadata
- Authors
- Sheahan, K. H., Wahlberg, E. A., & Gilbert, M. P.
- Affiliations
- University of Vermont Medical Center (US)
- Corresponding author
- Sheahan, Kelsey H
- Venue
- Postgraduate Medical Journal
- Publisher
- Oxford University Press (OUP)
- Published
- 2019-12-04
- Volume
- 96
- Issue
- 1133
- Pages
- 156-161
- ISSN
- 0032-5473 (ISSN-L)
- 1469-0756
- PMC
- PMC7042958
- OpenAlex
- W2992144798
- Cited by
- 194
- References
- 26
- Citations by year
- 2026: 10 · 2025: 28 · 2024: 31 · 2023: 27 · 2022: 43 · 2021: 47 · 2020: 8
- FWCI
- 19.88
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- Locations
- Postgraduate Medical Journal (publishedVersion, cc-by-nc)
- PubMed Central (publishedVersion, cc-by-nc)
- PubMed (publishedVersion)
- HighWire Press Open Archive (submittedVersion)
- Funders
- Sanofi
- Max-Planck-Gesellschaft
- Novo Nordisk
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes, Cardiovascular Risks, and Lipoproteins
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Heart Failure Treatment and Management
- Keywords
- GLP-1 receptor agonists, type 2 diabetes, lixisenatide, liraglutide, semaglutide, exenatide, albiglutide, dulaglutide, oral semaglutide, HbA1c, weight loss, hypoglycemia, treatment guidelines
- MeSH terms
- Glucagon-Like Peptide-1 Receptor, Glucagon-Like Peptide-1 Receptor Agonists, Cardiovascular Diseases, Clinical Trials as Topic, Diabetes Mellitus, Type 2, Humans, Hypoglycemic Agents, Medication Therapy Management
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
